Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

GP-BETAHISTINE TABLETS 24MG [SIN16812P]

Active ingredients: BETAHISTINE DIHYDROCHLORIDE

View product's general information
Last updated 16 September 2026

Product Info

GP-BETAHISTINE TABLETS 24MG

[SIN16812P]

Product information

Active Ingredient and Strength

BETAHISTINE DIHYDROCHLORIDE - 24 MG

Dosage Form

TABLET

Manufacturer and Country

GPAX PHARMACEUTICALS PRIVATE LTD - INDIA

Registration Number

SIN16812P

Licence Holder

GOLDPLUS UNIVERSAL PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

N07CA01

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

4.1 Therapeutic indications
Vertigo, tinnitus and hearing loss associated with Ménière's syndrome.

Dosing

4.2 Posology and method of administration

Posology

Adults:
The dosage for adults is 24–48mg divided over the day. The 24mg strength can be taken 2 times daily. Daily dose should not exceed 48mg. The dosage should be individually adapted according to the response. Improvement can sometimes only be observed after a couple of weeks of treatment.

Paediatric population: not recommended for use in children below 18 years due to insufficient data on safety and efficacy.

Renal impairment: There are no specific clinical trials available in this patient group.

Hepatic impairment: There are no specific clinical trials available in this patient group.

Method of Administration

The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses.

Contraindications

4.3 Contraindications
Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Phaeochromocytoma.